Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.
Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E. Lenders M, et al. Among authors: weidemann f. Orphanet J Rare Dis. 2016 Jun 29;11(1):88. doi: 10.1186/s13023-016-0473-4. Orphanet J Rare Dis. 2016. PMID: 27356758 Free PMC article.
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E. Weidemann F, et al. J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20. J Am Soc Nephrol. 2014. PMID: 24556354 Free PMC article.
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE. Biegstraaten M, et al. Among authors: weidemann f. Orphanet J Rare Dis. 2015 Mar 27;10:36. doi: 10.1186/s13023-015-0253-6. Orphanet J Rare Dis. 2015. PMID: 25885911 Free PMC article.
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E. Lenders M, et al. Among authors: weidemann f. Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z. Orphanet J Rare Dis. 2016. PMID: 27142856 Free PMC article.
Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J, Weidemann F. Kramer J, et al. Among authors: weidemann f. Curr Med Chem. 2018;25(13):1530-1537. doi: 10.2174/0929867324666170616102112. Curr Med Chem. 2018. PMID: 28618999 Review.
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F. Krämer J, et al. Among authors: weidemann f. Nephrol Dial Transplant. 2018 Aug 1;33(8):1362-1372. doi: 10.1093/ndt/gfx319. Nephrol Dial Transplant. 2018. PMID: 29186537
225 results